Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.

Prior treatment

• Previous exposure to anifrolumab;
• Documented diagnosis of severe or rapidly progressive Class III or IV glomerulonephritis requiring induction therapy \[mycophenolate mofetil (MMF)/cyclophosphamide (CYC) + high dose steroids\], isolated Class V lupus nephritis, or active severe or unstable neuropsychiatric lupus
• Currently participating in any interventional clinical trial with an investigational product;

Other

• Patients who are at LLDAS5 at the time of study entry;
• Inability to understand and sign the informed consent and to fill in patient questionnaires

• Provided informed consent to participate in the study;
• Aged 18 years or older;
• Fulfilled the 2019 EULAR/ACR classification criteria for SLE at the time of study entry;
• Prescribed anifrolumab for SLE treatment for the first time, according to the approved Italian label and reimbursement criteria;